NO970803L - Fremgangsmåte for identifisering av forbindelser egnet for behandling av autoimmune sykdommer - Google Patents

Fremgangsmåte for identifisering av forbindelser egnet for behandling av autoimmune sykdommer

Info

Publication number
NO970803L
NO970803L NO970803A NO970803A NO970803L NO 970803 L NO970803 L NO 970803L NO 970803 A NO970803 A NO 970803A NO 970803 A NO970803 A NO 970803A NO 970803 L NO970803 L NO 970803L
Authority
NO
Norway
Prior art keywords
ciita
methods
identifying compounds
treatment
compounds
Prior art date
Application number
NO970803A
Other languages
English (en)
Other versions
NO970803D0 (no
Inventor
Laurie H Glimcher
Hong Zhou
Iii John Douhan
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of NO970803D0 publication Critical patent/NO970803D0/no
Publication of NO970803L publication Critical patent/NO970803L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/395—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Saccharomyces
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Beskrevet er fremgangsmåter for å identifisere forbindelser som hemmer transkripsjonaktivering av CIITA og på denne måte heminer MHC klasse Il-genekspresjon. Slike forbindelser kan affisere induksjon av en itnmunrespons. Fremgangsmåtene benytter uavhengig aktiverings- og interaksjonsdomenene i CIITA. Fremgangs- måtene benytter også aktiverings- og interaks j onsdomene"ne av isotype-spesifikke CIITA-proteiner, noe som tillater identifikasjon av forbindelser som er isotype-spesif ikke inhibitorer av transkripsjon og som er hensiktsmessige for selektivt å affisere immunsystemet.
NO970803A 1994-08-24 1997-02-21 Fremgangsmåte for identifisering av forbindelser egnet for behandling av autoimmune sykdommer NO970803L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/295,502 US5672473A (en) 1994-08-24 1994-08-24 Methods of identifying compounds useful for treating autoimmune diseases
PCT/US1995/010691 WO1996006107A1 (en) 1994-08-24 1995-08-22 Methods of identifying compounds useful for treating autoimmune diseases

Publications (2)

Publication Number Publication Date
NO970803D0 NO970803D0 (no) 1997-02-21
NO970803L true NO970803L (no) 1997-04-21

Family

ID=23137979

Family Applications (1)

Application Number Title Priority Date Filing Date
NO970803A NO970803L (no) 1994-08-24 1997-02-21 Fremgangsmåte for identifisering av forbindelser egnet for behandling av autoimmune sykdommer

Country Status (18)

Country Link
US (1) US5672473A (no)
EP (1) EP0777677B1 (no)
JP (1) JPH10507908A (no)
KR (1) KR970705573A (no)
AT (1) ATE219099T1 (no)
AU (1) AU700235B2 (no)
CA (1) CA2197233C (no)
DE (1) DE69527073T2 (no)
ES (1) ES2178677T3 (no)
FI (1) FI970735A (no)
MX (1) MX9701295A (no)
NO (1) NO970803L (no)
NZ (1) NZ292369A (no)
PL (1) PL318812A1 (no)
PT (1) PT777677E (no)
RU (1) RU2160447C2 (no)
WO (1) WO1996006107A1 (no)
ZA (1) ZA957120B (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020155542A1 (en) * 1994-08-26 2002-10-24 Mach Bernard F. Inhibitors for suppressing the activity of proteins displaying CIITA activity, methods for their identification and pharmaceutical compositions
US5994082A (en) * 1994-08-26 1999-11-30 Mach; Bernard Methods for the identification of inhibitors which suppress the activity of proteins displaying CIITA activity
AU5795498A (en) * 1996-12-11 1998-07-03 University Of North Carolina At Chapel Hill, The Novel forms of class ii mhc transactivator (ciita)
US6426411B1 (en) * 1997-05-30 2002-07-30 Dana-Farber Cancer Institute PGC-1, a novel brown fat pparγ coactivator
US6410261B2 (en) * 1997-11-06 2002-06-25 President And Fellows Of Harvard College CIITA-interacting proteins and methods of use therefor
FR2775003A1 (fr) 1998-02-19 1999-08-20 Transgene Sa Methode de criblage de composes capables d'inhiber la fixation entre le facteur de transcription stat1 et le facteur de transcription usf1
AU4219899A (en) 1998-05-28 1999-12-13 President And Fellows Of Harvard College Methods and compositions relating to modulation of cartilage cell growth and/or differentiation by modulation of nfatp activity
US20050244849A1 (en) * 2000-12-15 2005-11-03 Genetics Institute, Llc Screening assays for rheumatoid arthritis
US20030125273A1 (en) * 2001-12-05 2003-07-03 Isis Pharmaceuticals Inc, Antisense modulation of MHC class II transactivator expression
WO2005049860A2 (en) * 2003-11-05 2005-06-02 Karolinska Innovations Ab Diagnostic and therapeutic methods and assays

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69429608T2 (de) * 1993-08-26 2002-09-12 Novimmune Sa, Genf/Geneve MHC-Klasse-II Transaktivator (CIITA) und dessen Anwendungen

Also Published As

Publication number Publication date
MX9701295A (es) 1997-05-31
KR970705573A (ko) 1997-10-09
PT777677E (pt) 2002-11-29
NZ292369A (en) 1999-01-28
EP0777677A1 (en) 1997-06-11
CA2197233C (en) 2001-02-20
DE69527073D1 (de) 2002-07-18
US5672473A (en) 1997-09-30
AU700235B2 (en) 1998-12-24
ATE219099T1 (de) 2002-06-15
EP0777677A4 (en) 1998-04-01
FI970735A (fi) 1997-04-21
AU3412695A (en) 1996-03-14
DE69527073T2 (de) 2003-01-23
RU2160447C2 (ru) 2000-12-10
ES2178677T3 (es) 2003-01-01
FI970735A0 (fi) 1997-02-21
EP0777677B1 (en) 2002-06-12
CA2197233A1 (en) 1996-02-29
PL318812A1 (en) 1997-07-07
JPH10507908A (ja) 1998-08-04
ZA957120B (en) 1996-03-26
NO970803D0 (no) 1997-02-21
WO1996006107A1 (en) 1996-02-29

Similar Documents

Publication Publication Date Title
BR9707819A (pt) Imunogenos peptidicos
AUPN568095A0 (en) Anti-Galalpha(1,3)Gal antibody binding peptides
DE69130289D1 (de) Therapeutische verwendung von actin-bindenden verbindungen
ATE245030T1 (de) Antigen-besierende heteropolymere zur behandlung von autoimmunkrankheiten mittels diesen
DE69631478D1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
NO970803L (no) Fremgangsmåte for identifisering av forbindelser egnet for behandling av autoimmune sykdommer
NO963785L (no) Fremgangsmåte for behandling av 5HT2B-reseptor-relaterte betingelser
DK0859957T3 (da) Patientspecifikke immunadsorbenser til ekstraporal apherese og fremgangsmåde til deres fremstilling
TR200102864T2 (tr) N”rolojik ya da n”ropsikiyatrik bozukluklarìn tedavisi i‡in y”ntem
DE69433243D1 (de) Verwendunf von ApoE zum Binden von TAU und MAP2c Proteinen und zur Behandlung von Alzheimer's Krankheit
ATE316136T1 (de) Nierenpolycystose-gen
ATE293994T1 (de) Multivalente rekombinante antikörper zur behandlung von hrv infektionen
MX9206339A (es) Nueva proteina inhibidora de trombina a partir de chinches de monte
DE69434072D1 (de) Regulierende nukleinsaeuresequenzen und verwendungen
FR2657005B1 (fr) Systeme d'enclouage pour le traitement des fractures notamment du type cervico-trochanteriennes et pertrochanteriennes.
IT1288184B1 (it) Procedimento per l'accorciamento del tempo di chiusura e dispositivo per l'attuazione del procedimento.
DE69625819D1 (de) Die verwendung von ondansetron zur herstellung eines medikamentes zur behandlung von tremor
SE9302990D0 (sv) Anordning vid markberedning

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application